GlassScriptPhysician profile
Cory L Conniff
NPI 1376539726
$17,198.68
in general payments reported to CMS, 2019-2025
47 companies · $2,539 in 2025
The $2,539 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,153 · 2020: $1,488 · 2021: $2,385 · 2022: $2,553 · 2023: $3,362 · 2024: $2,719 · 2025: $2,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,576 · Education: $43.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,575.51 |
| Education | $43.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,099.47 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Abbvie INC. | $1,627.53 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Horizon Therapeutics Plc | $1,614.12 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $1,363.47 | 2019-2025 | Simponi Aria, Tremfya |
| Novartis Pharmaceuticals Corporation | $1,333.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,168.07 | 2019-2025 | Orencia |
| Lilly USA, LLC | $958.72 | 2019-2025 | Taltz, Zepbound |
| Pfizer INC. | $842.89 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $642.13 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $533.20 | 2023-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $520.98 | 2019-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.99 | 2020-2023 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $320.45 | 2023-2025 | Strensiq |
| US Oncology Corporate, INC. | $314.28 | 2022-2023 | |
| Genzyme Corporation | $299.96 | 2019-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $279.18 | 2021-2025 | Saphnelo, Bevespi Aerosphere |
| Genentech USA, INC. | $175.10 | 2019-2025 | Actemra |
| Tersera Therapeutics LLC | $157.61 | 2022-2023 | Quzyttir |
| Glaxosmithkline, LLC. | $136.75 | 2021-2023 | Benlysta |
| Organon LLC | $131.30 | 2021-2025 | Hadlima |
| Fresenius Kabi USA, LLC | $115.57 | 2023-2024 | Idacio |
| Avanos Medical | $113.48 | 2022-2023 | Genvisc 850 Sodium Hyaluronate, Trivisc Sodium Hyaluronate |
| Sobi, INC | $112.07 | 2023-2025 | |
| Radius Health, INC. | $103.20 | 2019-2025 | Tymlos |
| Octapharma USA, INC. | $93.98 | 2024 | Panzyga |
| Actelion Pharmaceuticals US, INC. | $89.12 | 2021-2023 | Uptravi, Opsumit |
| Sandoz INC. | $84.28 | 2023-2024 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $75.30 | 2022-2025 | Entyvio, Hyqvia |
| Janssen Scientific Affairs, LLC | $68.80 | 2019-2021 | |
| Depuy Synthes Sales INC. | $67.41 | 2019-2024 | Monovisc |
| Fidia Pharma USA INC. | $62.83 | 2019-2022 | |
| Antares Pharma, INC. | $47.36 | 2019 | |
| Mallinckrodt Enterprises LLC | $45.84 | 2019 | |
| Celgene Corporation | $41.73 | 2019 | |
| Bioventus LLC | $41.39 | 2019-2024 | Supartz Fx Sodium Hyaluronate |
| Hikma Pharmaceuticals USA | $27.23 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $26.78 | 2023 | Truxima |
| Kyowa Kirin, INC. | $25.83 | 2025 | |
| Celltrion USA INC. | $23.71 | 2023 | Yuflyma |
| Orthogenrx INC. | $23.16 | 2021 | |
| Invivyd INC | $21.92 | 2025 | Pemgarda |
| Ferring Pharmaceuticals INC. | $14.41 | 2021 | |
| Aurinia Pharma U.S., INC. | $11.87 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Conniff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.